The Cooper Companies, Inc. (COO) AI Stock Analysis

The Cooper Companies, Inc., along with its subsidiaries, specializes in the development, manufacturing, and global distribution of contact lenses and medical devices. The company operates through two segments: CooperVision and CooperSurgical. CooperVision provides contact lenses, including spherical, toric, and multifocal lenses for vision impairments such as nearsightedness, farsightedness, astigmatism, presbyopia, and eye dryness. CooperSurgical focuses on family and women's healthcare, offering medical devices and services such as fertility solutions, genomic testing, diagnostic tools, contraception, and surgical instruments. Its offerings include products like PARAGARD, uterine manipulators, fertility consumables, and genetic testing technologies.

Revenue expanded from $2.92B in FY2021 to $4.09B in FY2025, reflecting a 5-year CAGR of 11.0% from FY2020 to FY2025. Annual top-line growth decelerated over this period, moderating from 20.2% in FY2021 to 5.1% in FY2025. Gross margin contracted to 60.7% in FY2025 from 66.6% in FY2024, while operating margin came in at 16.7%. Net income was $374.9M in FY2025, generating diluted EPS of $4.13. For the trailing twelve months ending July 31, 2026, revenue totaled $4.24B with an operating margin of 20.8% and EPS of $2.91. In the latest quarter, quarterly revenue growth was 0.6% year-over-year, while quarterly earnings grew 357.1%.

As of July 31, 2026, The Cooper Companies held $154.7M in cash and short-term investments against $2.54B in total debt, resulting in net debt of $2.39B. Shareholders' equity stood at $8.33B, with total assets of $12.67B. Liquidity metrics include a current ratio of 1.22 and a debt-to-equity ratio of 0.31. In FY2025, operating cash flow reached $796.1M and free cash flow was $433.7M. Capital allocation in FY2025 included capital expenditures of $362.4M and share buybacks of $290.1M, with the share count declining 3.1% over five years.

At a share price of $57.94, The Cooper Companies has a market capitalization of $11.02B and an enterprise value of $13.05B. The stock trades at a trailing P/E of 19.9x, a forward P/E of 11.3x, and an EV/EBITDA of 13.8x. These multiples sit below the median of its S&P 500 Healthcare peers, which post a trailing P/E of 28.9x, a forward P/E of 16.6x, and an EV/EBITDA of 15.7x. The company's price-to-sales ratio of 2.6x also compares to the peer median of 3.4x. Over the past year, COO posted a return of -19.0%, trailing the S&P 500 (SPY) return of 16.8%.

Wall Street analysts hold 3 Strong Buy, 2 Buy, and 12 Hold ratings, with no Sell or Strong Sell ratings. The mean price target is $65.80, representing 13.6% upside from the last close of $57.94. For the fiscal year ending October 31, 2026, the consensus EPS estimate is $4.53 on revenue of $4.24B. For the following fiscal year, 17 analysts project EPS of $4.69 on revenue of $4.41B. The company beat EPS estimates in all of the last 4 quarters, and the next earnings date is December 3, 2026.

This page is an AI-written research summary of The Cooper Companies, Inc. (COO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: COO income statement, COO balance sheet, COO key metrics, COO analyst forecast, COO chart. See the COO stock overview for the latest quote and news.